Eldec Pharmaceuticals

Executive Summary

Eldec Pharmaceuticals is a private biotechnology company headquartered in San Diego, focused on developing novel peptide therapeutics for chronic lung diseases. Its proprietary platform, the Lung Peptidome, identifies and optimizes naturally occurring peptides from lung lining fluid to target inflammation, tissue remodeling, and fibrosis. The lead candidate, ELD615, is a first-in-class Orai1 modulator designed to reverse existing lung damage, addressing a significant unmet need in diseases such as idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD). The company was founded in 2018 and operates in the RNA & Gene Therapy category, though its approach is peptide-based, leveraging endogenous mechanisms for high specificity and low toxicity. Although the company remains in early stages with no disclosed funding rounds or clinical trials, its innovative platform and first-in-class mechanism offer potential differentiation in a competitive landscape. Key risks include lack of clinical validation, private status with limited transparency, and the inherent challenges of drug development. With no publicly available pipeline milestones, the near-term outlook depends on advancing ELD615 into IND-enabling studies and securing partnerships or funding. The company's success hinges on demonstrating preclinical proof-of-concept for ELD615 and expanding its platform's applicability.

Upcoming Catalysts (preview)

• Q3 2026IND Filing for ELD61580% success
• H2 2026Partnership or Licensing Deal for Lung Peptidome Platform50% success
• Q2 2026Release of Preclinical Data for ELD61590% success